The New Blood Test for Alzheimer's (p-tau217): What It Means and Who Should Get It | Philadelphia

TL;DR30-second take

A new class of blood tests, led by one measuring a protein called p-tau217, can now detect the brain pathology of Alzheimer's disease, and in May 2025 the first such test was cleared by the FDA. The key thing to understand is that these tests detect amyloid and tau pathology in the brain, not dementia, and the two are not the same. Amyloid appears 15 to 20 years before symptoms and is common in healthy older people; about a third of cognitively normal people in their seventies have it, and many never develop dementia. So a positive test in a person without symptoms does not mean they have Alzheimer's or will get it. The test is cleared and recommended for people who already have cognitive symptoms being evaluated for the cause, where it can clarify the diagnosis and help decide about the new anti-amyloid drugs. It is not recommended for screening people without symptoms, because a result cannot yet change what you would do, it can cause serious anxiety, and it can affect life, disability, and long-term-care insurance, which no federal law prevents. Whether or not you test, the levers that lower dementia risk are the same.

TL;DR: A new generation of blood tests can now detect the biology of Alzheimer's disease, and in May 2025 the FDA cleared the first of them, built around a protein called p-tau217. This is a genuine advance, and it is also widely misunderstood. The single most important thing to hold onto is that these tests detect brain pathology, the amyloid plaques and tau tangles of Alzheimer's, and not dementia itself, which are different things. That pathology begins to accumulate 15 to 20 years before any symptoms, and it is common in healthy older people: roughly a third of cognitively normal people in their seventies carry amyloid in the brain, and a large share of them will never develop dementia. So a positive test in a person with no symptoms does not mean they have Alzheimer's or are destined to get it. The test earns its keep in a specific setting: a person who already has memory or thinking problems being worked up for the cause, where it can help sort Alzheimer's from other explanations and inform whether the new anti-amyloid drugs make sense. It is not recommended for screening people who feel fine, because a result cannot yet change what you would do about it, it can cause serious distress, and it can be used against you in life, disability, and long-term-care insurance, which no federal law prevents. And here is the freeing part: the things that lower your risk of dementia are the same whether you take the test or not.

What does the new Alzheimer's blood test measure?

The tests measure proteins in the blood that reflect what is happening in the brain, and the standout is p-tau217, a form of the tau protein that rises early in Alzheimer's and tracks both of the disease's hallmark changes, the amyloid plaques and the tau tangles. Some tests also read the ratio of two amyloid fragments in the blood, though that amyloid signal on its own is faint and easily thrown off by handling, which is why the strongest tests lead with p-tau217. What matters is that these markers correlate closely with the gold-standard measures of Alzheimer's pathology, the amyloid PET scan and the spinal-fluid test, with accuracy in study after study reaching the range of 90 percent and above for detecting amyloid in the brain.¹ ²

The distinction to carry through the rest of this article is what those markers do and do not represent. They report on brain pathology, the physical changes of Alzheimer's, and they correlate with those changes rather than with symptoms. A positive result means the plaques and tangles are probably there. It is a pathology test rather than a diagnosis, and certainly rather than a prediction, and the gap between having the pathology and having the disease is the whole story.

Is it FDA-approved, and where can you get it?

This is worth getting precise, because the language matters. In May 2025 the FDA cleared the first blood test for Alzheimer's, a test measuring the p-tau217 and amyloid ratio, a notable milestone.¹⁰ The careful word is cleared, not approved: the test went through the FDA's clearance pathway as an aid to diagnosis, and its cleared use is narrow. It is for adults aged 55 and older who already have cognitive symptoms and are being evaluated for Alzheimer's, as one input into that workup. It is explicitly not cleared as a screening test for people without symptoms, and it does not diagnose the other causes of dementia, such as vascular disease or Lewy body disease.

Alongside the cleared test, a few laboratories offer their own versions, including mass-spectrometry tests that combine p-tau217 with the amyloid ratio into a single score. These are laboratory-developed tests, validated by the labs that run them but not cleared by the FDA for a defined use, which is a different regulatory category worth understanding when a test is simply available to order. One of these was marketed directly to consumers, which drew sharp criticism from Alzheimer's specialists and led the company to add a step requiring that the person have symptoms and a risk factor. The availability of a test is not the same as a recommendation to take it, and that distinction is where most of the confusion, and most of the potential harm, lives.

If it is positive, do I have Alzheimer's?

Not necessarily, and this is the heart of the matter. Alzheimer's pathology begins to build up in the brain 15 to 20 years before any symptoms appear, and by the time people reach older age a striking number of them carry it without any trouble.³ In careful studies, the share of cognitively normal people who are amyloid-positive climbs from about 10 percent at age 50 to more than 40 percent by age 90, and at age 70 roughly a third of people with normal thinking already have amyloid in the brain.⁴ ⁵ Carrying the APOE4 risk gene shifts that curve earlier by many years. A large share of these people will live out their lives and never develop dementia.

What this means for a test result is the crux. Amyloid is necessary for Alzheimer's disease but it is not sufficient, so finding it in a person without symptoms tells you they are one of the sizable group who harbor the pathology, and it cannot tell you whether or when they will ever develop the disease. This is why a positive blood test in someone with no cognitive symptoms is so easy to misread: it feels like a diagnosis, but it is closer to learning that you have a risk factor whose timing and outcome remain unknown. The same result carries a very different meaning in a person who already has memory problems, where the pathology helps explain the symptoms, than in a person who feels well, where it explains nothing yet and predicts little.

Who should get this test?

The guidance from the field is clear and more restrained than the marketing. The Alzheimer's Association's first clinical practice guideline on these blood tests, published in 2025, recommends them for people who already have objective cognitive impairment and are being evaluated for its cause, used within specialized care and as one part of a full assessment rather than a stand-alone answer.⁷ The revised diagnostic criteria that now define Alzheimer's biologically make the same point that is so often lost: defining the disease by its biology does not mean testing everyone, and biomarker testing is recommended for symptomatic people in clinical care, rather than routine testing of people without symptoms outside of research.⁶

In that symptomatic setting the test does valuable work. When someone has memory or thinking changes, a p-tau217 test can help sort Alzheimer's from the many other, sometimes reversible, causes of cognitive symptoms, from thyroid disease and B12 deficiency to sleep apnea, depression, and medication effects. A clearly negative result makes Alzheimer's unlikely and can spare a person an invasive spinal tap or an expensive scan, while a clearly positive result can be confirmed and, when appropriate, open the door to treatment. It also has a specific modern role: the newer anti-amyloid antibody drugs, lecanemab and donanemab, are approved only for early symptomatic Alzheimer's with confirmed amyloid, so the blood test can help identify who might be a candidate before moving to a confirmatory scan.⁷

Why not test to get ahead of it?

This is the impulse to resist, and it is worth understanding why, because getting ahead of a disease is usually good advice and here it does not hold. The problem is a chain of three facts. First, there is no treatment proven to help a person who has amyloid in the brain but no symptoms; the anti-amyloid drugs are approved for people who already have early symptoms, they do not prevent the disease, and they carry a risk of brain swelling and small bleeds that is higher in APOE4 carriers, which is why they are reserved for symptomatic patients. Second, because nothing you would do changes based on the result, a positive test in a well person buys no benefit while it can cause serious anxiety or depression; the reassuring safety data on learning one's genetic or amyloid status come from research settings with careful screening and structured counseling, rather than from ordering a test online.⁹

Third, and most concrete for many readers, there is an insurance gap that is easy to overlook. Federal law limits how a health insurer or an employer can use your health information, but no federal law stops life insurance, disability insurance, or long-term-care insurance from using a positive Alzheimer's biomarker in their underwriting. For an affluent person buying those policies, a result sought out of curiosity can carry a serious financial cost. And a negative test is its own trap, because it offers false reassurance: it says nothing about vascular disease, other dementias, or the large share of dementia risk that comes from ordinary, modifiable factors. Put together, testing a person without symptoms today mostly creates downside, which is why no guideline recommends it outside of research.

What lowers your dementia risk, test or no test?

Longevity Medicine

A personalized longevity strategy starts with knowing your real baselines.

Start Your Longevity Assessment

Here is the part that should reframe the whole question, because it is where the true power sits. A landmark 2024 review concluded that around 45 percent of dementia worldwide is linked to fourteen modifiable risk factors, meaning nearly half of the risk runs through things that can be changed.⁸ The list is long and mostly familiar: hearing loss, high LDL cholesterol, high blood pressure, diabetes, obesity, physical inactivity, smoking, excessive alcohol, depression, social isolation, air pollution, head injury, less education, and vision loss. Two of the largest single levers, hearing loss and, newly recognized, LDL cholesterol, sit squarely in the reach of ordinary preventive care.

The point for anyone weighing the blood test is that each of these levers is proven, available now, and independent of any test result. Treating hearing loss, lowering apoB and LDL, controlling blood pressure and blood sugar, staying physically and socially active, protecting sleep, and not smoking all lower dementia risk whether your amyloid status is positive, negative, or unknown. The test cannot tell you to do anything you should not already be doing, and it would not change a single one of these actions. So the most useful move for a person worried about their brain is almost always to pour that worry into the prevention plan, where it does measurable good, rather than into a test that mostly generates uncertainty.

So should you get the Alzheimer's blood test?

The answer follows directly from everything above and comes down to whether you have symptoms and whether a result would change anything. If you have noticeable changes in memory or thinking and you are being evaluated for the cause, the test is a reasonable and useful part of that workup, best done with a clinician who can place it in context, because the result can meaningfully change the plan, by clarifying the diagnosis or informing whether an anti-amyloid drug is an option. That is the situation the test was built for.

If you feel well and simply want to know, the honest answer is that this is not the moment, because a result cannot yet change your management, it carries psychological and insurance downsides, and the prevention that would help you is available without it. Before anyone tests in a gray zone, a structured conversation is worth having, the kind a genetic counselor would lead: why do you want to know, what would you do differently, what are the insurance implications, and is there a treatment that hinges on the answer. For most people asking out of understandable worry, that conversation ends with redirecting the energy toward the fourteen levers that lower risk, and revisiting the test if and when symptoms or a treatment decision make it matter.

Guidance from the Clinic

"This is one of the most exciting advances in memory care in years, and also one of the easiest to misuse. When a patient comes to me with genuine memory changes, a p-tau217 test can be a valuable gift, because it helps me sort out whether Alzheimer's is driving the problem or whether it is something I can reverse, like a thyroid issue, a B12 deficiency, sleep apnea, or a medication, and it can tell us whether the newer drugs are even worth discussing. That is the test doing its job. What I steer people away from is testing when they feel fine and just want to peek at their future, because a positive result there does not change anything I can offer, it can be distressing, and most people do not realize it can affect their life and long-term-care insurance, which no federal law protects against. My honest counsel is usually the same: if you are worried about your brain, let's put that energy into the things that are proven to lower dementia risk, your hearing, your cholesterol, your blood pressure, your sleep, your activity, and let's use the test when you have symptoms or a treatment decision that it can inform. That is when knowing helps."

Key Takeaways

The new Alzheimer's blood tests, led by p-tau217, detect the brain pathology of Alzheimer's, the amyloid and tau changes, and correlate with PET and spinal-fluid measures; they report on pathology, not dementia, and not a prediction.
In May 2025 the FDA cleared the first such test as an aid to diagnosis in symptomatic adults 55 and older; cleared is not the same as approved, and it is not cleared for screening people without symptoms.
Amyloid is necessary but not sufficient for Alzheimer's: it appears 15 to 20 years before symptoms and is common in healthy older people, with about a third of cognitively normal people in their seventies carrying it, so a positive test in a symptom-free person does not mean disease.
The test is recommended for people with cognitive symptoms being evaluated for the cause, where it can clarify the diagnosis and inform anti-amyloid drug decisions; it is not recommended for screening people without symptoms, because a result cannot change management and carries anxiety and life, disability, and long-term-care insurance risks that no federal law prevents.
The levers that lower dementia risk, from treating hearing loss and lowering LDL cholesterol to controlling blood pressure and staying active, account for close to half of dementia risk, are proven and available now, and are the same whether or not you take the test.

Should You Test for APOE4? Your Alzheimer's Risk Gene - the genetic side of the same question, with the same testing trade-offs
The New Alzheimer's Drugs (Leqembi, Kisunla) - the anti-amyloid treatments the blood test can help gate access to
Alzheimer's Prevention and Cognitive Longevity - the fuller prevention plan the test cannot replace
Hearing Loss and Dementia: The Biggest Modifiable Risk - one of the largest levers on the modifiable-risk list
Brain Health: A Medicine 3.0 Approach - the pillar tying cognitive prevention together

Scientific References

Palmqvist S, Janelidze S, Quiroz YT, et al. "Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders." JAMA. 2020;324(8):772-781.
Ashton NJ, Brum WS, Di Molfetta G, et al. "Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology." JAMA Neurology. 2024;81(3):255-263.
Bateman RJ, Xiong C, Benzinger TLS, et al. "Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease." New England Journal of Medicine. 2012;367(9):795-804.
Jansen WJ, Ossenkoppele R, Knol DL, et al. "Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-Analysis." JAMA. 2015;313(19):1924-1938.
Jansen WJ, Janssen O, Tijms BM, et al. "Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum." JAMA Neurology. 2022;79(3):228-243.
Jack CR Jr, Andrews JS, Beach TG, et al. "Revised Criteria for Diagnosis and Staging of Alzheimer's Disease: Alzheimer's Association Workgroup." Alzheimer's & Dementia. 2024;20(8):5143-5169.
Palmqvist S, Whitson HE, Allen LA, et al. "Alzheimer's Association Clinical Practice Guideline on the Use of Blood-Based Biomarkers in the Diagnostic Workup of Suspected Alzheimer's Disease Within Specialized Care Settings." Alzheimer's & Dementia. 2025.
Livingston G, Huntley J, Liu KY, et al. "Dementia Prevention, Intervention, and Care: 2024 Report of the Lancet Standing Commission." Lancet. 2024;404(10452):572-628.
Green RC, Roberts JS, Cupples LA, et al. "Disclosure of APOE Genotype for Risk of Alzheimer's Disease (REVEAL Study)." New England Journal of Medicine. 2009;361(3):245-254.
US Food and Drug Administration. "510(k) K242706: Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio." Cleared May 16, 2025.

Medical Disclaimer: This resource provides clinical context for educational purposes and is not medical advice. A blood biomarker cannot diagnose or exclude Alzheimer's disease on its own, and the decision to test is individual, with meaningful psychological and insurance implications. Do not test or act on a result without a clinician's guidance. In Precision Medicine there is no one-size-fits-all; whether an Alzheimer's blood test is right for you depends on your symptoms, your goals, and your circumstances. Consult Dr. Ash or your own physician about cognitive testing and dementia prevention.

Fishtown Medicine | Longevity

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

Not necessarily. The test detects the brain pathology of Alzheimer's, the amyloid and tau changes, and that pathology is common in healthy older people; about a third of cognitively normal people in their seventies have amyloid in the brain, and many never develop dementia. So a positive result in a person with no symptoms means the pathology is probably present, but it cannot say whether or when dementia would follow. The same positive result means much more in someone who already has memory problems, where it helps explain the symptoms, than in someone who feels well, where it predicts little.

The precise term is FDA-cleared, not approved, and the difference matters. In May 2025 the FDA cleared the first blood test for Alzheimer's as an aid to diagnosis in adults 55 and older who already have cognitive symptoms. It is not cleared as a screening test for people without symptoms. Some laboratories also offer their own versions, which are validated by the labs but not FDA-cleared for a defined use. So a test being available to order is not the same as a recommendation that you take it.

For a person without symptoms, generally no. There is no treatment proven to help someone who has amyloid in the brain but no symptoms, so a positive result cannot change your management, while it can cause serious anxiety and can affect life, disability, and long-term-care insurance. A negative result is also misleading, since it says nothing about other dementias or the large, modifiable share of dementia risk. The prevention that would help you is available whether or not you test. The test is for people with symptoms being worked up, rather than for getting ahead of the disease.

Yes, in a way many people do not expect. Federal law limits how health insurers and employers can use your health information, but no federal law stops life insurance, disability insurance, or long-term-care insurance from using a positive Alzheimer's biomarker. Those policies can use a positive Alzheimer's biomarker in their underwriting. For someone who is buying or plans to buy that kind of coverage, a test taken out of curiosity can carry a genuine financial downside, which is one of the reasons testing without symptoms is discouraged.

Modifiable risk factors account for close to half of dementia risk, and the levers are proven and available now: treating hearing loss, lowering LDL cholesterol and apoB, controlling blood pressure and blood sugar, staying physically and socially active, protecting sleep, not smoking, limiting alcohol, and protecting your head and your vision. None of these depends on a blood test, and the test result would not change any of them. So if you are worried about your brain, the highest-value move is to work the prevention plan, which does measurable good, rather than to chase a test that mostly generates uncertainty.

Deep-Dive Questions

Because amyloid is one ingredient in a longer, slower, and still incompletely understood process, and having the ingredient does not guarantee the outcome. Alzheimer's disease appears to unfold over decades, with amyloid plaques accumulating first, followed years later by the spread of tau tangles, loss of brain cells, and eventually the symptoms of dementia, and many people move partway along that path without ever reaching its end within their lifetime. The brain also has reserve and resilience that vary from person to person, so two people with the same amount of amyloid can have very different futures depending on their other risks, their vascular health, their cognitive reserve, and simple factors like how long they live. This is why researchers say amyloid is necessary but not sufficient: you do not get Alzheimer's dementia without the pathology, but plenty of people have the pathology and never get the dementia. A blood test captures the presence of the ingredient, rather than the trajectory of the whole process, which is why a positive result in a symptom-free person raises a question instead of delivering an answer.

No, and this is a subtle point that is easy to get backward. The revised criteria do define Alzheimer's as a biological process that can be identified by biomarkers even before symptoms, which is a scientifically important step that helps research and standardizes diagnosis. But defining a disease by its biology is a statement about what the disease is, rather than a recommendation to go looking for it in everyone. The same experts who wrote those criteria are explicit that biomarker testing belongs in the evaluation of people who have symptoms, and that testing people without symptoms outside of research is not recommended, because a positive result in that setting cannot yet be acted on and carries the harms described above. Conflating "we can now define the disease biologically" with "everyone should get the biomarker" is the central error the marketing encourages, and holding the two apart is what keeps the advance from becoming a source of harm.

Because the safety comes from the context as much as from the information. In research studies, learning one's amyloid or gene status has generally not caused serious lasting distress, which is reassuring, but those studies are built around safeguards that a direct-to-consumer order lacks: participants are screened for depression and suicide risk and excluded if they are vulnerable, the result is delivered by a trained counselor who prepares the person beforehand and supports them afterward, and there is a clear framework for what the result does and does not mean. Strip away that scaffolding and the same piece of information arrives very differently, stripped of the screening, counseling, and context that made it safe, in a person who may be anxious or depressed to begin with, and indeed the distress after disclosure is higher in people who already have cognitive symptoms. So the claim that disclosure is safe is true only inside the setting that made it safe, and it does not transfer to a test bought online. The information is identical; the container is not, and with this kind of news the container is much of what determines whether it helps or harms.

Because prevention acts on risk you can change, while the test reports on a status you cannot yet do anything about, and for lowering your odds of dementia the first is far more powerful than the second. Close to half of dementia risk traces to modifiable factors, and several of them, hearing loss and high LDL cholesterol among the strongest, are things ordinary care can address directly, with treatments that improve the rest of your health at the same time. Correcting hearing loss, lowering apoB and LDL, controlling blood pressure and blood sugar, and staying active and connected each nudge your dementia risk down and do so regardless of what any biomarker shows. The blood test, by contrast, tells you about pathology that, in an asymptomatic person, points to no action that is not already on that prevention list. So the counterintuitive truth is that the humble, whole-body levers move your true risk more than the brain-specific test moves your knowledge, and unlike the test, they carry no insurance or psychological cost. For a person who wants to protect their mind, that is where the leverage is.

Ready when you are